Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

639 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.
Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS. Friedberg JW, et al. Among authors: sims p. Br J Haematol. 2009 Aug;146(3):282-91. doi: 10.1111/j.1365-2141.2009.07773.x. Epub 2009 Jun 10. Br J Haematol. 2009. PMID: 19519691 Free PMC article. Clinical Trial.
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.
Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS. Friedberg JW, et al. Among authors: sims p. Blood. 2005 Jan 15;105(2):489-95. doi: 10.1182/blood-2004-06-2156. Epub 2004 Sep 9. Blood. 2005. PMID: 15358617 Free article. Clinical Trial.
CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.
Haining WN, Davies J, Kanzler H, Drury L, Brenn T, Evans J, Angelosanto J, Rivoli S, Russell K, George S, Sims P, Neuberg D, Li X, Kutok J, Morgan J, Wen P, Demetri G, Coffman RL, Nadler LM. Haining WN, et al. Among authors: sims p. Clin Cancer Res. 2008 Sep 1;14(17):5626-34. doi: 10.1158/1078-0432.CCR-08-0526. Clin Cancer Res. 2008. PMID: 18765557 Clinical Trial.
Glioma-induced alterations in excitatory neurons are reversed by mTOR inhibition.
Goldberg AR, Dovas A, Torres D, Pereira B, Viswanathan A, Das Sharma S, Mela A, Merricks EM, Megino-Luque C, McInvale JJ, Olabarria M, Shokooh LA, Zhao HT, Chen C, Kotidis C, Calvaresi P, Banu MA, Razavilar A, Sudhakar TD, Saxena A, Chokran C, Humala N, Mahajan A, Xu W, Metz JB, Bushong EA, Boassa D, Ellisman MH, Hillman EMC, Hargus G, Bravo-Cordero JJ, McKhann GM 2nd, Gill BJA, Rosenfeld SS, Schevon CA, Bruce JN, Sims PA, Peterka DS, Canoll P. Goldberg AR, et al. Among authors: sims pa. Neuron. 2025 Jan 16:S0896-6273(24)00926-7. doi: 10.1016/j.neuron.2024.12.026. Online ahead of print. Neuron. 2025. PMID: 39837324
Receiver design for the REACH global 21-cm signal experiment.
Roque ILV, Razavi-Ghods N, Carey SH, Ely JA, Handley W, Magro A, Chiello R, Huang T, Alexander P, Anstey D, Bernardi G, Bevins HTJ, Cavillot J, Croukamp W, Cumner J, de Lera Acedo E, de Villiers DIL, Fialkov A, Gessey-Jones T, Gueuning Q, Josaitis AT, Kulkarni G, Leeney SAK, Maiolino R, Meerburg PD, Mittal S, Pagano M, Pegwal S, Pieterse C, Pritchard JR, Saxena A, Scheutwinkel KH, Scott P, Shen E, Sims PH, Smirnov O, Spinelli M, Zarb-Adami K. Roque ILV, et al. Among authors: sims ph. Exp Astron (Dordr). 2025;59(1):7. doi: 10.1007/s10686-024-09975-3. Epub 2025 Jan 17. Exp Astron (Dordr). 2025. PMID: 39834569 Free PMC article.
639 results